Techcyte reshuffles board as it eyes growth push

Techcyte said Aug. 20 it reorganized its board of directors to support expansion of its AI-powered digital pathology platform. The move adds two new directors with healthcare and operational experience as the company seeks broader adoption and profitability.

Why it matters: - Techcyte is trying to scale its digital pathology platform faster while deepening partnerships with laboratories and other industry players. - The board changes add clinical, commercial and operational experience that could shape the company’s path to broader adoption and profitability.

What happened: - Techcyte announced a reorganization of its board of directors on Aug. 20, 2026. - Ralph Yarro, a Techcyte founder, will remain chairman. - Continuing directors include Karine Sellam, vice president and global head of business development at Zoetis; Ben Cahoon, Techcyte CEO; and Dr. Mohamed Salama, chief medical officer at Sonic Healthcare USA. - New directors are Mark McNabb, head of the Private Capital Group at the Van Tuyl Family Office, and Jim Rogers, CEO of Mayo Clinic Digital Pathology.

The details: - Jim Rogers leads Mayo Clinic Digital Pathology, which focuses on scaling digital pathology through scanning, storage, artificial intelligence and algorithm development. - Rogers said pathology is entering an important period of transformation and he wants to help bring digital pathology innovation into broader use. - Mark McNabb leads the Private Capital Group at the Van Tuyl Family Office and has more than three decades of experience guiding large organizations through growth and transformation. - McNabb’s background includes senior roles at Nissan, Mercedes-Benz USA, General Motors, Maserati and Volkswagen Group of America, plus founder and CEO experience at Electrify America. - McNabb said he sees a significant opportunity ahead and wants to help build the operational foundation needed to scale it. - Techcyte said the reorganized board will help the company navigate expansion of its platform, deeper strategic partnerships and wider deployment of AI-powered digital pathology.

Between the lines: - The board reset signals Techcyte is moving from product development toward operational scale and commercial execution. - Adding leaders with healthcare innovation, commercialization and transformation experience suggests the company wants outside expertise as it pursues growth. - Ben Cahoon said the board brings clinical, technical, commercial and operational experience needed to help Techcyte grow rapidly, reach profitability and deliver lasting value to laboratories.

What's next: - Techcyte is expected to use the new board structure to support platform expansion and partnership growth. - The company also aims to bring AI-powered digital pathology to more laboratories. - Techcyte’s anatomic and clinical pathology platform remains for Research Use Only in the United States.

The bottom line: - Techcyte is reshaping its board to support the next stage of growth as it pushes for broader adoption of its AI-powered digital pathology platform.